StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.07−0.32 (-0.93%)

Close on Nov 18, 2026Market cap $2.25BP/E 6.3Yield –

Lakefront Biotherapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2025 it was €320.88M, up 333.1% from the year before. The highest annual figure on record is €320.88M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025€320.88M+333.1%
FY2024Dec 31, 2024€74.08M-65.0%
FY2023Dec 31, 2023€211.70M–
FY2022Dec 31, 2022-€217.99M–
FY2021Dec 31, 2021-€103.23M–
FY2020Dec 31, 2020-€305.44M-303.8%
FY2019Dec 31, 2019€149.85M–
FY2018Dec 31, 2018-€29.26M–
FY2017Dec 31, 2017-€115.70M-314.2%
FY2016Dec 31, 2016€54.01M–
FY2015Dec 31, 2015-€118.41M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2021Jun 30, 2021-€64.33M–
Q2 FY2020Jun 30, 2020-€115.04M–
Q2 FY2019Jun 30, 2019-€47.25M–
Q2 FY2018Jun 30, 2018-€21.77M–
Q2 FY2017Jun 30, 2017-€35.64M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?